Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (6104)	10/19/1998 3:38:00 PM
From: Anthony Wong	Respond to of 9523

Celebrex Sales Monsanto's Celebrex might reach sales of $1 billion in its first 12 months on the market if the U.S. Food and Drug Administration classifies it as a new kind of painkiller, said Hemant Shah, a drug industry analyst. Even without that distinction, the drug could have $300 million to $500 million in its first full year on the market, he said. Monsanto's situation now is similar to that of Warner- Lambert Co. a few years ago, Shah said. Warner-Lambert today reported that third-quarter profit rose 49 percent to $296 million as sales of its cholesterol-reducing drug Lipitor more than doubled to $569 million. Warner-Lambert last year introduced Lipitor, working with Pfizer Inc. as a marketing partner. Monsanto too has an agreement with Pfizer, the maker of the impotence pill Viagra, to introduce its drug, Celebrex. ''This is another Warner-Lambert story where one drug can make a big difference,'' Shah said of Monsanto. ''The numbers could be huge (for Celebrex.) It all depends on the FDA.'' Excerpt from a Bloomberg aticle on MTC dated October 19, 1998 quote.bloomberg.com